The FAM179A gene has recently been screened as a new fusion partner fusing to the anaplastic lymphoma kinase gene (ALK) in plasma cell-free DNA (cfDNA) of patients with non-small-cell lung cancer (NSCLC). However, the response of patients with NSCLC harboring the FAM179A–ALK fusion to ALK inhibitors remains unknown. In this study we report a novel FAM179A–ALK rearrangement variant (F1, A19) identified by next-generation sequencing in an NSCLC patient with multiple brain metastases (M1c). This patient responded sensitively to lorlatinib as evaluated by brain MRI and chest CT, followed up using plasma cfDNA. The conclusion is that we found a novel FAM179A–ALK rearrangement variant (F1, A19) and provided evidence of its sensitivity to ALK inhibitors. READ ARTICLE
Lung Cancer DOI:10.1016/j.lungcan.2020.06.026
Authors: Jing Yan, Xijian Zhou, Dejian Pan
